Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 2

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 2
---
x®-UM                                                                                                                                                                                                                                                                                              
 •Mental health diagnoses— IDgenetix®                                                                                                                                                                                                                                                                                         |     |   |     |                                                                                                                                                                                                                        |     |                  |     |                           |     |                                                                        |     |                   |

| $332M                     
 in revenue                
 51% year-over-year growth |     |                                                                |
| 96,071                    
 delivered test reports    
 36% year-over-year growth |     |                                                                |
|                           |     | $293M                                                          
 in cash, cash equivalents and marketable investment securities 
 as of December 31, 2024                                        |
|                           |     | 157                                                            
 peer-reviewed                                                  
 studies published                                              
 across all franchises to date                                  |

#### Castle Biosciences 2025 Proxy Statement1

#### Proxy Summary

#### Our Test Portfolio
Our portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology and ophthalmology and a pharmacogenomic (“PGx”) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions.

Maintaining commercial success for our existing test portfolio requires generating ongoing evidence, such as clinical performance and clinical use documentation, to support appropriate clinician adoption, reimbursement success and guideline inclusion. The clinical validity and utility of our test portfolio is supported by peer-reviewed publications and ongoing clinical studies. Collectively, approximately 157 peer-reviewed articles have been published demonstrating the analytical validity, clinical validity and clinical utility of the tests in our portfolio.

#### 2024

#### STOCKHOLDER OUTREACH
The Board is committed to sound corporate governance, which we believe requires feedback from our stockholders to inform the Board’s decisions and guide our overall approach to governance. Our stockholder outreach in 2024 provided the Board with valuable insights into our stockholders’ perspectives on our executive compensation program and other matters of importance. We endeavor to maintain sound compensation and corporate governance practices and will continue to evaluate our executive compensation program to further align it with the long-term interests of our stockholders. We are committed to understanding stockholders’ perspectives and anticipate ongoing stockholder outreach.

For many years, we followed a consistent approach to the design of our executive compensation program. At our 2024 annual meeting of stockholders, we asked our stockholders to indicate their support for the compensation of our named executive officers by casting a non-binding, advisory vote “FOR” such compensation as described in the proxy statement (commonly known as a “Say-on